At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Eleni Efstathiou, MD, PhD, of The University of Texas MD Anderson Cancer Center, Houston, TX, discusses a study that evaluated the clinical and biological heterogeneity of response and resistance to neoadjuvant abiraterone acetate, a prodrug of abiraterone, a CYP17 inhibitor that lowers serum testosterone, plus leuprolide acetate, a luteinizing hormone-releasing hormone agonist (LHRHa), versus LHRHa for patients with localised high-risk prostate cancer.
Neoadjuvant abiraterone acetate plus leuprolide acetate in localised high-risk prostate cancer
23rd July 2015
Oncology
Please rate the quality of this content
We are sorry that this content was not interesting for you!
Let us improve this content!
Tell us how we can improve this content?